• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Tuesday, May 30, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Surveillance after surgery does not improve outcomes for patients with glioblastoma

Bioengineer by Bioengineer
February 26, 2020
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Retrospective study revealed no benefit for precautionary screenings after tumor removal

IMAGE

Credit: MU Health Care


Glioblastoma is an aggressive and deadly brain cancer. Although improved treatment protocols have doubled the survival rate over the past 20 years, glioblastoma tumors usually grow back. After surgeons remove the tumor, patients typically undergo surveillance imaging within 48 hours followed by regular screenings to monitor for recurrence. However, a retrospective study from the University of Missouri School of Medicine and MU Health Care showed patients who underwent surveillance imaging after surgery did not have better outcomes than patients who did not have imaging and returned when they felt symptoms of recurrence.

“Patients who undergo regular imaging can become nervous or anxious in the days or weeks leading up to their imaging appointment,” said N. Scott Litofsky, MD, professor and chief of neurological surgery at the MU School of Medicine and MU Health Care. “While surveillance is good, maybe we can change our protocols to make patients more comfortable and give them more control of the process but still deliver quality care.”

Litofsky’s research team reviewed 74 cases at MU Health Care. Of those, 47 patients underwent routine surveillance and 27 returned when they felt symptoms of recurrence. Litofsky found the median survival without a worsening condition was 6.1 months for the surveillance group and 6.0 for the symptomatic group. Post-recurrence survival rates were 6.4 months for surveillance and 7.7 months for symptomatic cases.

“We have a lot of patients who come from a long distance, and our general philosophy of care is to provide regular follow-up visits,” Litofsky said. “The hypothesis was patients would do better if we did regular surveillance. The results indicated that for this population of patients, the outcome was equivalent whether they had surveillance or showed up when they had symptoms.”

Litofsky said less patient surveillance testing could improve patient convenience, reduce cost and ease pre-imaging anxiety.

“Sometimes we do things because they seem to be the right thing to do, even if the evidence suggests maybe we don’t need to do it,” Litofsky said. “We may need to change our paradigm on how we are taking care of these patients.”

Litofsky is now planning a pilot study to link patient-reported outcomes identified through a questionnaire to clinic visits for patients. Then he’ll examine if the patient-reported outcomes are superior to clinic visits that included surveillance imaging.

“Maybe down the road, we could use a combination of reported outcomes and surveillance so we can reduce the amount of time the patients need to spend coming to appointments,” he said.

Litofsky’s study, “Does Surveillance-Detected Disease Progression Yield Superior Patient Outcomes in High-Grade Glioma?” was recently published by the journal World Neurosurgery.

###

Research reported in this publication was supported by the University of Missouri Research Council Summer Research Fellowship and Head for the Cure Foundation philanthropic gift. The authors of the study declare that they have no conflicts of interest. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Media Contact
Eric Maze
[email protected]
573-884-3656

Related Journal Article

http://dx.doi.org/10.1016/j.wneu.2019.12.001

Tags: cancerMedicine/HealthneurobiologySurgery
Share12Tweet8Share2ShareShareShare2

Related Posts

Jonathan Cedernaes, MD Ph.D. and Associate Professor in Medical Cell Biology at Uppsala University

Junk food may impair our deep sleep

May 30, 2023
(C) Azelle Hawdon

Scientists unveil RNA-guided mechanisms driving cell fate

May 30, 2023

Obesity increases risk of mental disorders throughout life

May 30, 2023

Researchers confirm the protective effect of hydrogen inhalation on declining brain function under hindlimb unloading conditions and disclose the underlying mechanism

May 30, 2023
Please login to join discussion

POPULAR NEWS

  • plants

    Plants remove cancer causing toxins from air

    39 shares
    Share 16 Tweet 10
  • Element creation in the lab deepens understanding of surface explosions on neutron stars

    36 shares
    Share 14 Tweet 9
  • Groundbreaking study uncovers first evidence of long-term directionality in the origination of human mutation, fundamentally challenging Neo-Darwinism

    115 shares
    Share 46 Tweet 29
  • How life and geology worked together to forge Earth’s nutrient rich crust

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Scientists identify how some angiogenic drugs used to treat cancer and heart disease cause vascular disease

CSI Singapore researchers uncover potential novel therapeutic targets against natural killer/T-cell lymphoma

Deconstructing the role of MALAT1 in MAPK-Signaling in melanoma

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 50 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In